Research
Hormonal
Abdominoplasty following GLP-1 RA-induced massive weight loss shows a trend toward a lower overall complication rate (20% vs 40%) compared to postbariatric surgery.
Practitioners may consider GLP-1 RA therapy as a safer option for patients seeking abdominoplasty after significant weight loss.
StrongQualifiesmedium confidence
The overall complication rate showed a trend toward lower rates in the GLP-1 RA cohort (20% versus 40%; OR, 0.38 [95% CI, 0.09 to 1.54] [ P = 0.301]).
Why this rating
Based on a retrospective comparative case series design.
Source
Abdominoplasty Outcomes after GLP-1 Agonist–Induced versus Postbariatric Massive Weight Loss: A Retrospective Comparative Case Series
Or Friedman et al. · Plastic & Reconstructive Surgery · 2025
DOI 10.1097/prs.0000000000012523
cohort · n=40Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →